Home > News > Venture firms still don't see the nanotech in biosciences
October 1st, 2003
Venture firms still don't see the nanotech in biosciences
Abstract:
Timing is everything, say Oregon's venture fund managers. The state of nanotechnology in the biosciences is too early for venture capital investing, believes Gerry Langeler, of Seattle-based OVP Venture Partners, the oldest venture firm in the Pacific Northwest, currently with $195 million to invest.
Source:
SmallTimes
Bookmark:
| Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||